Aravind A Menon1, Sandeep Sahay2, Lewis E Braverman3, Harrison W Farber4. 1. Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA. aamenon@bwh.harvard.edu. 2. Houston Methodist Hospital Lung Center, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX, USA. 3. Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, MA, USA. 4. Pulmonary, Critical Care and Sleep Medicine, Tufts University Medical Center, Boston, MA, USA.
Abstract
INTRODUCTION: Epoprostenol, a synthetic prostaglandin I2 (PGI2) analog, has been the mainstay of treatment for severe pulmonary arterial hypertension (PAH) for the last two decades. Treprostinil, another synthetic prostaglandin analog, and selexipag, an oral selective Inositol Phosphate (IP) prostacyclin receptor agonist, have also been approved for treatment of PAH. Prostacyclin and its analogs cause a variety of side effects in patients with PAH; however, thyroid dysfunction is rarely reported. METHODS: After treating an index case of thyroid dysfunction occurring after initiation of epoprostenol, we reviewed our databases of PAH patients treated with epoprostenol, treprostinil or selexipag to identify the occurrence of this association. RESULTS: We identified six cases of thyroid dysfunction in our cohort: five after initiation of an intravenous prostacyclin (epoprostenol) and one after initiation of an oral prostacyclin receptor agonist (selexipag). Four of the patients presented with hyperthyroidism and two with a large autoimmune goiter. Graves' disease was seen in three patients, Hashimoto's disease in two patients and thyrotoxicosis in one patient. CONCLUSION: Therapy with medications targeting the prostacyclin pathway is a potential risk factor for the development of symptomatic thyroid disease.
INTRODUCTION:Epoprostenol, a synthetic prostaglandin I2 (PGI2) analog, has been the mainstay of treatment for severe pulmonary arterial hypertension (PAH) for the last two decades. Treprostinil, another synthetic prostaglandin analog, and selexipag, an oral selective Inositol Phosphate (IP) prostacyclin receptor agonist, have also been approved for treatment of PAH. Prostacyclin and its analogs cause a variety of side effects in patients with PAH; however, thyroid dysfunction is rarely reported. METHODS: After treating an index case of thyroid dysfunction occurring after initiation of epoprostenol, we reviewed our databases of PAHpatients treated with epoprostenol, treprostinil or selexipag to identify the occurrence of this association. RESULTS: We identified six cases of thyroid dysfunction in our cohort: five after initiation of an intravenous prostacyclin (epoprostenol) and one after initiation of an oral prostacyclin receptor agonist (selexipag). Four of the patients presented with hyperthyroidism and two with a large autoimmune goiter. Graves' disease was seen in three patients, Hashimoto's disease in two patients and thyrotoxicosis in one patient. CONCLUSION: Therapy with medications targeting the prostacyclin pathway is a potential risk factor for the development of symptomatic thyroid disease.
Authors: Olivier Sitbon; Richard Channick; Kelly M Chin; Aline Frey; Sean Gaine; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Irene M Lang; Ralph Preiss; Lewis J Rubin; Lilla Di Scala; Victor Tapson; Igor Adzerikho; Jinming Liu; Olga Moiseeva; Xiaofeng Zeng; Gérald Simonneau; Vallerie V McLaughlin Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Lewis J Rubin; David B Badesch; Thomas R Fleming; Nazzareno Galiè; Gerald Simonneau; Hossein A Ghofrani; Michael Oakes; Gary Layton; Marjana Serdarevic-Pehar; Vallerie V McLaughlin; Robyn J Barst Journal: Chest Date: 2011-05-05 Impact factor: 9.410
Authors: David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon Journal: Chest Date: 2009-10-16 Impact factor: 9.410
Authors: N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau Journal: Lancet Date: 2008-06-21 Impact factor: 79.321